CompletedPHASE1, PHASE2NCT00742625
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Eyal Attar, MDCancer and Leukemia Group B
- Intervention
- daunorubicin hydrochloride(drug)
- Enrollment
- 95 enrolled
- Eligibility
- 60-75 years · All sexes
- Timeline
- 2008 – 2012
Study locations (22)
- Washington Hospital Center, Washington D.C., District of Columbia, United States
- Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C., District of Columbia, United States
- Florida Hospital, Orlando, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Eastern Maine Medical Center, Bangor, Maine, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Missouri - Ellis Fischel, Columbia, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- North Shore University Hospital, Manhasset, New York, United States
- North Shore-LIJ Health System CCOP, Manhasset, New York, United States
- Long Island Jewish Medical Center, New Hyde Park, New York, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00742625 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.